Last year, we had interviewed Parul Oza, Managing Director of CRMO Pharmatech, to better understand ICH Q11, and the US Food and Drug Administration's adoption of the same. The ICH Q11 are guidelines for the development and manufacture of drug substances (chemical entities and biotechnological/biological entities).
